{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:28:10Z","timestamp":1789518490625,"version":"build-2803163510"},"reference-count":116,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy. It is increasingly recognized as a multisystem hypothalamic encephalopathy, rooted in the selective loss or dysfunction of orexin neurons, yet extending across motor, psychiatric, metabolic, and autonomic domains. Over the past two decades, convergent genetic, neuropathological, and immunological evidence has positioned narcolepsy type 1 as increasingly consistent with the spectrum of immune-mediated neurological diseases while challenging the validity of current classifications that hinge on cataplexy or multiple sleep latency testing. Borderland phenotypes, variable orexin biology, and post-infectious or secondary forms underscore the limitations of rigid categorical nosologies and support a spectrum-based framework. Advances in immunology, imaging, and systems biology highlight the limitations of purely symptomatic treatment and support the exploration of mechanism-based interventions, including orexin receptor agonism, immune-targeted strategies in early disease, and regenerative or circuit-repair approaches. In this narrative review, based on literature identified through searches of PubMed, Web of Science, and Scopus through December 2025, we synthesize evidence across epidemiology, pathophysiology, diagnosis, and therapy, and propose an integrative clinical algorithm that moves beyond categorical diagnoses toward a phenotype\u2013biomarker\u2013mechanism stratification model. We suggest that narcolepsy should no longer be considered a rare curiosity of sleep medicine but rather a model disorder illuminating the vulnerability of hypothalamic circuits and the complex interplay between sleep, emotion and immunity.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1799520","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:10:18Z","timestamp":1775128218000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine"],"prefix":"10.3389","volume":"17","author":[{"given":"Oscar","family":"Arias-Carri\u00f3n","sequence":"first","affiliation":[{"name":"Divisi\u00f3n de Neurociencias Cl\u00ednica, Instituto Nacional de Rehabilitaci\u00f3n Luis Guillermo Ibarra Ibarra","place":["Mexico City, Mexico"]},{"name":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Ortega-Robles","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Neurociencias Cl\u00ednica, Instituto Nacional de Rehabilitaci\u00f3n Luis Guillermo Ibarra Ibarra","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Romano","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Investigaci\u00f3n en Ingenier\u00eda M\u00e9dica, Instituto Nacional de Rehabilitaci\u00f3n Luis Guillermo Ibarra Ibarra","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Pineda","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Reumatolog\u00eda, Instituto Nacional de Rehabilitaci\u00f3n Luis Guillermo Ibarra Ibarra","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1107632","article-title":"Progress of autonomic disturbances in narcolepsy type 1","volume":"14","author":"Wang","year":"2023","journal-title":"Front Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0540-1","article-title":"T cells in patients with narcolepsy target self-antigens of hypocretin neurons","volume":"562","author":"Latorre","year":"2018","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41467-019-08774-1","article-title":"Cd8(+) T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens","volume":"10","author":"Pedersen","year":"2019","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1818150116","article-title":"Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy","volume":"115","author":"Luo","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2017.06.006","article-title":"Incidence of narcolepsy after H1n1 influenza and vaccinations: systematic review and meta-analysis","volume":"38","author":"Sarkanen","year":"2018","journal-title":"Sleep Med Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41598-018-36942-8","article-title":"Hplc analysis of csf hypocretin-1 in type 1 and 2 narcolepsy","volume":"9","author":"Sakai","year":"2019","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition: highlights and modifications","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"key":"B9","volume-title":"International classification of sleep disorders \u2013 third edition, text revision (Icsd-3-tr)","year":"2023"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301940","article-title":"Oral orexin receptor 2 agonist in narcolepsy type 1","volume":"389","author":"Dauvilliers","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405847","article-title":"Oveporexton, an oral orexin receptor 2-selective agonist, in narcolepsy type 1","volume":"392","author":"Dauvilliers","year":"2025","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e70083","DOI":"10.1111\/jsr.70083","article-title":"Orexin restoration in narcolepsy: breakthroughs in cellular therapy","volume":"35","author":"Ortega-Robles","year":"2025","journal-title":"J Sleep Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.cub.2023.03.077","article-title":"Immortal orexin cell transplants restore motor-arousal synchrony during cataplexy","volume":"33","author":"Pintwala","year":"2023","journal-title":"Curr Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz091","article-title":"Prevalence and incidence of narcolepsy in a us health care claims database, 2008-2010","volume":"42","author":"Scheer","year":"2019","journal-title":"Sleep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","article-title":"The epidemiology of narcolepsy in olmsted county, minnesota: A population-based study","volume":"25","author":"Silber","year":"2002","journal-title":"Sleep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000525282","article-title":"Heterogeneity in estimates of incidence and prevalence of narcolepsy: A systematic review and meta-regression analysis","volume":"56","author":"Wang","year":"2022","journal-title":"Neuroepidemiology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleepx.2023.100095","article-title":"Prevalence and incidence of narcolepsy symptoms in the us general population","volume":"6","author":"Ohayon","year":"2023","journal-title":"Sleep Medicine: X"},{"key":"B18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sleep.2024.11.034","article-title":"Epidemiology of narcolepsy and idiopathic hypersomnia in Japan: A retrospective analysis of health insurance claims from the Japan medical data center","volume":"126","author":"Kadotani","year":"2025","journal-title":"Sleep Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40675-020-00195-7","article-title":"Narcolepsy presentation in diverse populations: an update","volume":"6","author":"Spruyt","year":"2020","journal-title":"Curr Sleep Med Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2016.12.005","article-title":"Epidemiology and pathophysiology of childhood narcolepsy","volume":"25","author":"Dye","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000110316","article-title":"A community survey of neurological disorders in Saudi Arabia: the thugbah study","volume":"12","author":"Rajeh","year":"1993","journal-title":". Neuroepidemiology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2012.06.006","article-title":"Health, social, and economic consequences of narcolepsy: A controlled national study evaluating the societal effect on patients and their partners","volume":"13","author":"Jennum","year":"2012","journal-title":"Sleep Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2017.03.029","article-title":"Morbidity and mortality of middle-aged and elderly narcoleptics","volume":"36","author":"Jennum","year":"2017","journal-title":"Sleep Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.57.11.2029","article-title":"Age at onset of narcolepsy in two large populations of patients in France and quebec","volume":"57","author":"Dauvilliers","year":"2001","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1550152","article-title":"Narcolepsy during childhood: an update","volume":"46","author":"Rocca","year":"2015","journal-title":"Neuropediatrics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/17.suppl_8.s17","article-title":"Narcolepsy in children","volume":"17","author":"Challamel","year":"1994","journal-title":"Sleep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/children9070974","article-title":"Pediatric narcolepsy-a practical review","volume":"9","author":"Chung","year":"2022","journal-title":"Children (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001051","article-title":"Primary progressive narcolepsy type 1: the other side of the coin","volume":"83","author":"Pizza","year":"2014","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12044","article-title":"Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: A european narcolepsy network study","volume":"22","author":"Luca","year":"2013","journal-title":"J Sleep Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.2080","article-title":"Predictors of hypocretin (Orexin) deficiency in narcolepsy without cataplexy","volume":"35","author":"Andlauer","year":"2012","journal-title":"Sleep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.2922","article-title":"Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia","volume":"9","author":"Trotti","year":"2013","journal-title":"J Clin Sleep Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsx164","article-title":"Test-retest reliability of the multiple sleep latency test in central disorders of hypersomnolence","volume":"40","author":"Lopez","year":"2017","journal-title":"Sleep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bd1344","article-title":"Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment","volume":"73","author":"Dauvilliers","year":"2009","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(84)92742-9","article-title":"Genetic markers in narcolepsy","volume":"2","author":"Langdon","year":"1984","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1038\/s41467-023-36120-z","article-title":"Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy","volume":"14","author":"Ollila","year":"2023","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2630-12.2012","article-title":"Narcolepsy: neural mechanisms of sleepiness and cataplexy","volume":"32","author":"Burgess","year":"2012","journal-title":"J Neurosci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.smrv.2005.03.004","article-title":"Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin\/orexin system","volume":"9","author":"Nishino","year":"2005","journal-title":"Sleep Med Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab285","article-title":"Narcolepsy with intermediate cerebrospinal level of hypocretin-1","volume":"45","author":"Postiglione","year":"2022","journal-title":"Sleep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.10576","article-title":"Progressive narcolepsy: how to deal with intermediate hypocretin-1 values","volume":"19","author":"Ricordeau","year":"2023","journal-title":"J Clin Sleep Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41439-018-0033-7","article-title":"Genetics of narcolepsy","volume":"6","author":"Miyagawa","year":"2019","journal-title":"Hum Genome Var"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10464","DOI":"10.1038\/s41598-023-37511-4","article-title":"Narcolepsy type I-associated DNA methylation and gene expression changes in the human leukocyte antigen region","volume":"13","author":"Yoshida-Tanaka","year":"2023","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249405","article-title":"The transcriptomics profiling of blood cd4 and cd8 T-cells in narcolepsy type I","volume":"14","author":"Khajavi","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41577-023-00902-9","article-title":"The immunopathogenesis of narcolepsy type 1","volume":"24","author":"Liblau","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2024.101993","article-title":"Recent insights into the pathophysiology of narcolepsy type 1","volume":"78","author":"Vringer","year":"2024","journal-title":"Sleep Med Rev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e70984","DOI":"10.1002\/brb3.70984","article-title":"Orexin deficiency in narcolepsy: molecular mechanisms, clinical phenotypes, and emerging therapeutic frontiers","volume":"15","author":"Rauf","year":"2025","journal-title":"Brain Behav"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e2207531119","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients","volume":"119","author":"Evans","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.imed.2024.11.005","article-title":"Neuroimaging in narcolepsy","volume":"5","author":"Ding","year":"2025","journal-title":"Intelligent Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101962","article-title":"Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches","volume":"78","author":"Freeman","year":"2025","journal-title":"Semin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ana.24019","article-title":"Increase of histaminergic tuberomammillary neurons in narcolepsy","volume":"74","author":"Valko","year":"2013","journal-title":"Ann Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2023.02.003","article-title":"Genetics and epigenetics of rare hypersomnia","volume":"39","author":"Mogavero","year":"2023","journal-title":"Trends Genet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e2220911120","DOI":"10.1073\/pnas.2220911120","article-title":"Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy","volume":"120","author":"Seifinejad","year":"2023","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaf278","article-title":"DNA methylation and multi-omics profiling of T cells uncovers chemotactic pathways and proliferation-linked hypomethylation in narcolepsy type 1","volume":"48","author":"Shimada","year":"2025","journal-title":"Sleep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-022-00298-w","article-title":"A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia","volume":"7","author":"Miyagawa","year":"2022","journal-title":"NPJ Genom Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(14)70075-4","article-title":"Narcolepsy as an autoimmune disease: the role of H1n1 infection and vaccination","volume":"13","author":"Partinen","year":"2014","journal-title":"Lancet Neurol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/32.12.1548","article-title":"Narcolepsy and streptococcal infections","volume":"32","author":"Longstreth","year":"2009","journal-title":"Sleep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"As03 adjuvanted ah1n1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PloS One"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e7370","DOI":"10.1002\/ccr3.7370","article-title":"Narcolepsy following covid-19: A case report and review of potential mechanisms","volume":"11","author":"Roya","year":"2023","journal-title":"Clin Case Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1444753","article-title":"Associations between T-cell traits and narcolepsy type 1: new insights from a mendelian randomization study","volume":"15","author":"Chen","year":"2024","journal-title":"Front Neurol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12374","article-title":"The european narcolepsy network (Eu-nn) database","volume":"25","author":"Khatami","year":"2016","journal-title":"J Sleep Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-024-01141-9","article-title":"Narcolepsy: beyond the classic pentad","volume":"39","author":"Morse","year":"2025","journal-title":"CNS Drugs"},{"key":"B64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11325-025-03259-6","article-title":"What is it like to live with narcolepsy? A scoping review","volume":"29","author":"Hlodak","year":"2025","journal-title":"Sleep Breath"},{"key":"B65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40263-024-01142-8","article-title":"A survey of people living with narcolepsy in the USA: path to diagnosis, quality of life, and treatment landscape from the patient\u2019s perspective","volume":"39","author":"Ortiz","year":"2025","journal-title":"CNS Drugs"},{"key":"B66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5664\/JCSM.1076","article-title":"Reward-seeking behavior in human narcolepsy","volume":"7","author":"Dimitrova","year":"2011","journal-title":"J Clin Sleep Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1475029","article-title":"Narcolepsy in early childhood: A case report and a mini review","volume":"12","author":"Liu","year":"2024","journal-title":"Front Pediatr"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/neurosci4040022","article-title":"Exploring the Literature on Narcolepsy: Insights into the Sleep Disorder That Strikes during the Day","volume":"4","author":"Matota","year":"2023","journal-title":"NeuroSci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15060382","article-title":"Alteration of metabolic profile in patients with narcolepsy type 1","volume":"15","author":"Hakim","year":"2025","journal-title":"Metabolites"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25512","article-title":"Narcolepsy in children: sleep disorders in children, a rapidly evolving field seeking consensus","volume":"57","author":"Dye","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ctn8030025","article-title":"Pediatric narcolepsy type 1: A state-of-the-art review","volume":"8","author":"Baldini","year":"2024","journal-title":"Clin Trans Neurosci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11940-017-0459-0","article-title":"Cataplexy and its mimics: clinical recognition and management","volume":"19","author":"Pillen","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2021.01.009","article-title":"Orexin-a measurement in narcolepsy: A stability study and a comparison of lc-ms\/ms and immunoassays","volume":"90","author":"Lindstrom","year":"2021","journal-title":"Clin Biochem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad173","article-title":"Larger hypothalamic volume in narcolepsy type 1","volume":"46","author":"Juvodden","year":"2023","journal-title":"Sleep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2023.08.001","article-title":"Narcolepsies, update in 2023","volume":"179","author":"Barateau","year":"2023","journal-title":"Rev Neurol (Paris)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12780","article-title":"Measurement of cerebrospinal fluid orexin-a (Hypocretin-1) by enzyme-linked immunosorbent assay: A comparison with radioimmunoassay","volume":"72","author":"Ono","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac052","article-title":"Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1","volume":"45","author":"van der Hoeven","year":"2022","journal-title":"Sleep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2011.10.002","article-title":"Use of actigraphy for assessment in pediatric sleep research","volume":"16","author":"Meltzer","year":"2012","journal-title":"Sleep Med Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-040323-031929","article-title":"Orexin receptor antagonism: normalizing sleep architecture in old age and disease","volume":"64","author":"Kron","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1700983114","article-title":"Hypocretin (Orexin) is critical in sustaining theta\/gamma-rich waking behaviors that drive sleep need","volume":"114","author":"Vassalli","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1523\/eneuro.0474-23.2024","article-title":"Whole brain mapping of orexin receptor mrna expression visualized by branched in situ hybridization chain reaction","volume":"11","author":"Tsuneoka","year":"2024","journal-title":". eNeuro"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.cub.2025.03.040","article-title":"An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions","volume":"35","author":"Ishikawa","year":"2025","journal-title":"Curr Biol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e2301951120","DOI":"10.1073\/pnas.2301951120","article-title":"Deficiency of orexin signaling during sleep is involved in abnormal rem sleep architecture in narcolepsy","volume":"120","author":"Ito","year":"2023","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102748","article-title":"Hypothalamus and amygdala functional connectivity at rest in narcolepsy type 1","volume":"31","author":"Ballotta","year":"2021","journal-title":"NeuroImage Clin"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0488","article-title":"Distinct convergent brain alterations in sleep disorders and sleep deprivation: A meta-analysis","volume":"82","author":"Reimann","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/s41598-023-29488-x","article-title":"Activation of the rostral nucleus accumbens shell by optogenetics induces cataplexy-like behavior in orexin neuron-ablated mice","volume":"13","author":"Kawashima","year":"2023","journal-title":"Sci Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e2501578122","DOI":"10.1073\/pnas.2501578122","article-title":"Orexin effect on physiological pulsations of the human brain","volume":"122","author":"Jarvela","year":"2025","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216302","article-title":"Pharmacological interventions for excessive daytime sleepiness in adults with narcolepsy: A systematic review and network meta-analysis","volume":"11","author":"Chien","year":"2022","journal-title":"J Clin Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2024.101976","article-title":"Rem sleep in narcolepsy","volume":"77","author":"Thorpy","year":"2024","journal-title":"Sleep Med Rev"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.5664\/jcsm.9384","article-title":"Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea","volume":"17","author":"Weaver","year":"2021","journal-title":"J Clin Sleep Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2147\/NSS.S412793","article-title":"Long-term treatment of narcolepsy and idiopathic hypersomnia with low-sodium oxybate","volume":"15","author":"Schneider","year":"2023","journal-title":"Nat Sci Sleep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102843","article-title":"Comparative efficacy, safety and benefit\/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: A network meta-analysis","volume":"76","author":"Pepin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.05.003","article-title":"The wake-promoting drug modafinil prevents motor impairment in sickness behavior induced by lps in mice: role for dopaminergic D1 receptor","volume":"81","author":"Zager","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/514351","article-title":"Armodafinil versus modafinil in patients of excessive sleepiness associated with shift work sleep disorder: A randomized double blind multicentric clinical trial","volume":"2011","author":"Tembe","year":"2011","journal-title":"Neurol Res Int"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01040-5","article-title":"Solriamfetol: A review in excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnoea","volume":"37","author":"Hoy","year":"2023","journal-title":"CNS Drugs"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e24937","DOI":"10.7759\/cureus.24937","article-title":"Solriamfetol for the use of narcolepsy: A systematic review","volume":"14","author":"Iturburu","year":"2022","journal-title":"Cureus"},{"key":"B98","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40263-024-01144-6","article-title":"Sodium oxybate: practical considerations and patient perspectives","volume":"39","author":"Lavender","year":"2025","journal-title":"CNS Drugs"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac042","article-title":"Response to: once-nightly sodium oxybate (Ft218) in the treatment of narcolepsy: A letter to the editor commenting on the recent publication by C","volume":"45","author":"Kushida","year":"2022","journal-title":"Kushida Et al. Sleep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111185","article-title":"Characterization and treatment patterns of patients treated with immediate-release sodium oxybate for narcolepsy: A propensity score-matched cohort study","volume":"135","author":"Lipford","year":"2025","journal-title":"J Clin Neurosci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e240031","DOI":"10.57264\/cer-2024-0031","article-title":"Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: A plain language summary","volume":"13","author":"Dauvilliers","year":"2024","journal-title":"J Comp Eff Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e14415","DOI":"10.1111\/jsr.14415","article-title":"Trends and variation in issuance of high-cost narcolepsy drugs by nhs england organisations and regions from 2019 to 2022","volume":"34","author":"van Someren","year":"2025","journal-title":"J Sleep Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003724.pub3","article-title":"Antidepressant drugs for narcolepsy","volume":"2008","author":"Vignatelli","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2014.01.021","article-title":"Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: A chart review","volume":"15","author":"Leu-Semenescu","year":"2014","journal-title":"Sleep Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(16)30333-7","article-title":"Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: A randomised, double-blind, placebo-controlled trial","volume":"16","author":"Szakacs","year":"2017","journal-title":"Lancet Neurol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105522","article-title":"Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: A meta-analysis from randomized controlled trials","volume":"167","author":"Wang","year":"2021","journal-title":"Pharmacol Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00036-4","article-title":"Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: A double-blind, randomised, placebo-controlled trial","volume":"22","author":"Dauvilliers","year":"2023","journal-title":"Lancet Neurol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.10.050","article-title":"Results of the solriamfetol\u2019s effect on cognitive health in apnea participants during a randomized placebo-controlled study (Sharp): A randomized placebo-controlled double-blind repeated-measures crossover phase iv clinical trial of the effect of the wake-promoting agent solriamfetol on cognitive function in osa with excessive daytime sleepiness and cognitive impairment","volume":"167","author":"Van Dongen","year":"2025","journal-title":"Chest"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00745-7","article-title":"A patient-centric clinical trial design to comprehensively evaluate low-sodium oxybate in people with idiopathic hypersomnia or narcolepsy","volume":"14","author":"Nichols","year":"2025","journal-title":"Neurol Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2025.106602","article-title":"Weight changes during treatment with low-sodium oxybate in two phase 3 clinical studies in participants with narcolepsy or idiopathic hypersomnia","volume":"133","author":"Foldvary-Schaefer","year":"2025","journal-title":"Sleep Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e16095","DOI":"10.7759\/cureus.16095","article-title":"Efficacy of pitolisant on the treatment of narcolepsy: A systematic review","volume":"13","author":"Fabara","year":"2021","journal-title":"Cureus"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz174","article-title":"Long-term use of pitolisant to treat patients with narcolepsy: harmony iii study","volume":"42","author":"Dauvilliers","year":"2019","journal-title":"Sleep"},{"key":"B113","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.122.001449","article-title":"Tak-994, a novel orally available brain-penetrant orexin 2 receptor-selective agonist, suppresses fragmentation of wakefulness and cataplexy-like episodes in mouse models of narcolepsy","volume":"385","author":"Ishikawa","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173464","article-title":"Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model","volume":"220","author":"Ishikawa","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000005375","article-title":"Tak-925 (Danavorexton), an orexin receptor 2 agonist, reduces opioid-induced respiratory depression and sedation without affecting analgesia in healthy men","volume":"142","author":"van Lemmen","year":"2025","journal-title":"Anesthesiology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e14150","DOI":"10.1111\/jsr.14150","article-title":"Eating disorders in narcolepsy type 1: evidence from a cross-sectional italian study","volume":"33","author":"Baldini","year":"2024","journal-title":"J Sleep Res"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1799520\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:10:20Z","timestamp":1775128220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1799520\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":116,"alternative-id":["10.3389\/fpsyt.2026.1799520"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1799520","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1799520"}}